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Abstract
Steroid-induced osteoporosis is a textbook example of the secondary type of this medical condition. Glucocorticosteroids suppress bone
formation by their direct and indirect effect on osteoblasts, osteoclasts and osteocytes, increasing their resorption and, eventually, leading
to negative bone balance. A clinical problem arises regarding the fact that approximately 50% of patients on chronic steroid therapy
undergo asymptomatic bone fractures. The treatment mode includes minimising the dose of administered steroids, encouraging an im-
proved lifestyle and supplementation with adequate calcium and vitamin D3 doses. Bisphosphonates are a group of medical agents used
both to prevent and treat steroid-induced osteoporosis, although new therapies have also become available in recent years.
(Pol J Endocrinol 2011; 62 (1): 38–44)
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Streszczenie
Osteoporoza posteroidowa jest modelowym przykładem osteoporozy wtórnej. Glukortykosteroidy poprzez bezpośredni i pośredni wpływ
na osteoblasty, osteoklasty oraz osteocyty hamują formowanie kości, zwiększając ich resorpcję, doprowadzając finalnie do ujemnego
bilansu kostnego. Problem kliniczny narasta w związku z faktem, że około 50% pacjentów długotrwale stosujących steroidy ulega asymp-
tomatycznym złamaniom kości. Leczenie pacjentów polega na minimalizowaniu dawki stosowanych steroidów, poprawie stylu życia
i suplementacji adekwatną dawką wapnia i witaminy D3. Bisfosfoniany są najlepiej przebadaną grupą leków stosowanych zarówno
w prewencji, jak i terapii osteoporozy posteroidowej, choć znajdują też zastosowanie nowe formy terapii.
(Endokrynol Pol 2011; 62 (1): 38–44)
Słowa kluczowe: osteoporoza posteroidowa, mężczyźni, kobiety, leczenie, prewencja
The study was performed within the Research Programme of the Medical University of Łódź No. 502-16-816.
Introduction
Glucorticosteroids were discovered early in the 20th cen-
tury. The first reports on the effects of cortisol on bone
tissue were presented by Cushing in 1932 [1]. Cortisone
was isolated in 1936–1940 and cortisol in 1939 [2, 3].
However, the development of a synthesis of deriva-
tives of those compounds, with much stronger immu-
nosuppressive and anti-inflammatory effects but with
smaller mineralcorticoid activity, led to their broad ap-
plication in the therapy of numerous diseases, includ-
ing autoimmunological, rheumatological, gastrologi-
cal and neoplasmic diseases and in cases of organ trans-
plantation [4].
An analysis, carried out in the UK of 1.6 million pre-
scriptions for oral steroids issued over a ten year peri-
od, showed these agents are used in 0.9% of the gener-
al population and in approximately 2.5% of patients
aged 70 to 79, i.e. the time when adverse symptoms may
overlap with changes related to the ageing process [5].
Although glucocorticosteroids are important therapeu-
tic agents, their adverse effects, manifested during their
chronic use, should be kept in mind, including their
unfavourable effects on bone tissue. Our knowledge
regarding the necessity of prophylactics is still unsatis-
factory, which is why prophylactic treatment has been
proposed to only 5% of subjects on oral glucocorticos-
teroid therapy [5].
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Aetiopathogenesis
Steroid-induced osteoporosis is a textbook example of
secondary osteoporosis [6, 7]. Glucocorticosteroids, via
their direct and indirect effects on osteoblasts, osteo-
clasts and osteocytes, inhibit bone formation, increas-
ing their resorption and, eventually, leading to nega-
tive bone balance [8] (Fig. 1). In direct steroid effects on
osteoclasts, the role of the recently discovered RANKL-
-osteoprotegerin system is emphasised, while the
PPARg2 system, Wnt signal and caspase-3 activation
influence the activities that steroids exert on osteoblasts.
Caspase-3 activation plays an important role in enhanc-
ing the apoptosis of osteocytes, until quite recently re-
garded as inactive bone tissue cells [9]. The process of
bone mass loss, observed in the course of steroid thera-
py, begins rapidly during the first few months, then
slows after the first year of treatment, to finally stabilise
at an annual rate of 2–5% [10, 11].
Fracture risk
The fact that 30–50% of steroid-administered patients
experience asymptomatic bone fractures is a significant
clinical problem of chronic steroid therapy, i.e. therapy
lasting longer than three months [12, 13]. There is a pos-
itive correlation between daily dose and fracture risk.
The fracture risk rises rapidly 3–6 months after the on-
set of steroid therapy, dropping down again when the
therapy ceases [14].
Glucocorticoids increase the risk of all fractures in
all age groups, including young people, regardless of
bone mineral density, earlier fractures in history or gen-
der [8, 12]. A meta-analysis of a population of 42,000
men and women found that bone density changes, re-
sulting from steroids used both currently and previous-
ly, increased the fracture risk, especially with regards
to the femoral neck. The risk of fractures is higher in
younger subjects than in women after the menopause,
irrespective of earlier fracture episodes [12]. According
to epidemiological data, subjects exposed to system ste-
roids experience a doubling in the incidence of femoral
neck and forearm fractures, while spinal fracture rates
are higher than in the untreated population [15].
It is also known that spinal fracture is an indepen-
dent risk factor of subsequent fractures, as well as those
in other areas [14]. The fracture risk rises at even such
a small daily dose of prednisolone as 2.5–7.5 mg; addi-
tionally, a relationship has been demonstrated between
the fracture risk and the cumulative dose [16, 17]. An
analysis of a group of 244,235 female patients vs. an iden-
tical control group found that the annual risk of frac-
tures at a prednisolone dose of 2.5–7.5 mg/day was 1.77
(CI 1.55–2.02), rising to 2.27 at a dose of 7.5 mg (CI 1.94–
Figure 1. Pathophysiology of changes in steroid-induced osteoporosis according to Canalis et al. [8] with own modification
Rycina 1. Zmiany patofizjologiczne w osteoporozie posteroidowej na podstawie pracy Canalis i wsp. [8] w modyfikacji własnej
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–2.66) [18]. When using an agent equivalent to pred-
nisolone at a dose of 10 mg/day over a period longer
than 90 days, the risk of femoral neck fracture is seven
times higher and the risk of spinal fracture is 17 times
higher [19].
Van Staa et al. [18] emphasised that in predisposed
subjects, even a dose of less than 2.5 mg may increase
fracture risk. Faced with this data, it is a particular chal-
lenge to precisely determine a dose which would leave
bone tissue unaffected.
This fact has influenced the final approach to ste-
roid-induced bone fracture risk, including also the cal-
culators evaluating ten year fracture risk, namely that
steroids used for at least three months are a significant
fracture risk factor [20–24].
It should be underlined that the levels of prophylac-
tics, even in such prophylactics-oriented countries as the
UK (14%) or Iceland (51%), are unsatisfactory [18, 25].
We must remember that most diseases in which ste-
roid administration is indicated themselves increase the
risk of osteoporosis, for example rheumatoid, chronic
pulmonary and inflammatory intestinal diseases or the
post-transplantation period [26–28].
No increased fracture risk has been demonstrated
with the use of nasal or local steroid application (e.g. as
an ointment) or in inhalatory forms, except the daily
dose corresponding to 7.5 mg of prednisolone (an equiv-
alent of 1,875 µg of budesonide or beclomethasone [29].
It has, however, been demonstrated that bone min-
eral density (BMD) is lower both with chronic applica-
tion of inhalatory steroids with intermediate doses of
oral steroids, and with continuous, combined use of
inhalatory steroids with oral steroids [30–32]. Follow-
ing clinical observations and according to steroid dos-
es, asthmatic patients were divided into groups of low,
medium and high risk of osteoporosis [33]. The low risk
group included patients taking inhalatory steroids,
equivalent to a daily beclomethasone dose £ 800 mg/
/day in adults or £ 400 mg/day in children. The medium
risk group featured patients with asthma, receiving in-
halatory steroids in a dose > 800 mg/day in adults and
> 400 mg/day in children. The high risk group comprised
patients using systemic steroids four times a year or in
daily oral doses, both as chronic therapies. This group
included subjects using nasal and inhalatory steroids
in combination with their oral forms.
Prophylactics and therapy
Even though the understanding of steroid therapy com-
plications continues to grow, neither osteoporosis pro-
phylactics nor treatment of the disease is yet optimal
[34]. However, the situation, viewed in the context of
the last few years, has demonstrated some improve-
ment. An evaluation of patients treated during 1995 to-
1998 against others treated 2001 to 2003 found out that
the number of densitometric examinations tripled and
the quantity of drugs used doubled.
In turn, it has been found in the United States that
only 10% of patients on oral steroid therapy had had
densitometry performed, while only 15% of patients
had been receiving treatment other than hormonal re-
placement therapy (HRT) [35].
It is worth emphasising that only one in three  pa-
tients had received any information about the counter-
measures against osteoporosis necessary with steroid
administration, only  half of them had been receiving
appropriate doses of calcium, and only one third had
received sufficient vitamin D supplementation [36].
Bearing all this in mind, doctors should be regularly
reminded about the need for prevention with prior
densitometric evaluation of bone status being per-
formed in patients before steroid therapy application.
The goals of post-steroid osteoporosis treatment in-
clude preservation of bone mineral density, counter-
acting bone mass loss, post-fracture pain control, mus-
cular force increase and improved lifestyle [10]. The
American Society of Rheumatology introduced recom-
mendations in 2001 concerning both the prevention and
therapy of post-steroid osteoporosis. All steroid-using
patients should receive supplementation with calcium
preparations (approximately 1 g daily) and with vita-
min D (800 IU/d). Patients treated with medium and
high doses of glucocorticosteroids should receive active
forms of vitamin D (e.g. alphacalcidiol 1 mg/d or calcitriol
0.5 mg/d), in addition to calcium supplementation.
Regarding the treatment of both men and post-
menopausal women, bisphosphonates is the therapy of
choice, while in cases of hypogonadism, it is hormonal
replacement therapy [10]. Alendronate, risedronate and
teriparatide are the medical agents approved in Europe
for osteoporosis treatment in men with increased frac-
ture risk [37–39]. Indications for osteoporosis prophy-
lactics and treatment implementation in the course of
steroid therapy differ greatly, despite numerous at-
tempts at systematisation [40–49] (Table I). All the rec-
ommendations emphasise the need for prevention dur-
ing continuous use of oral steroids. Intermittent thera-
py is still the subject of debate as to the best therapeutic
protocols. A similar situation is seen with inhalatory ste-
roids, taking into account the scarcity of data on an in-
creased fracture risk in the course of their application
[32, 50]. The divergent recommendations result from
differences in particular health care systems, the vary-
ing availability of densitometric examinations, and fairly
strong evidence for the efficacy of post-steroid os-
teoporosis therapy [42]. In the UK, primary prevention
protocols are recommended in all men and women over
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the age of 65 and all patients with fractures in their his-
tory, while in the USA, it concerns every person start-
ing steroid therapy. In the UK, recommendations cov-
er subjects using oral steroids for at least three months
with an unspecified dose limit, while in the United Sates,
this recommendation applies to subjects receiving ste-
roids for at least six months at a dose ≥ 5 mg of pred-
nisolone. Similar differences occur in imaging exami-
nations. The American recommendations indicate the
need for densitometric evaluation of all patients before
therapy implementation, emphasising the role of the
examination in monitoring. In the UK on the other hand,
densitometry is not a requirement in primary preven-
tion but should be performed to qualify patients to sec-
ondary prevention. In US recommendations, a densit-
ometry T-score £ –1.0 (£ –1.5 in UK) requires pharma-
cological intervention. Polish recommendations have
been systematised, taking into account local experience
and the particular needs of our country [40, 45].
Bisphosphonates
These agents are most frequently used both for prophy-
lactics of steroid-induced osteoporosis and to treat the
disease [9, 43, 44, 51]. Etidronate is registered in Europe
and in Canada only, while alendronate, risedronate and
zoledronate are widely applied [9]. The data shows that
a statistically significant anti-fracture effect in the spine
is observed after 24 months of alendronate, and after
12 months of etidronate or risedronate administration
[52–54]. Such agents as clodronate, ibandronate and pa-
midronate improve BMD, but there is no proper data
concerning their possible anti-fracture effects [55, 56]. In-
travenous forms of these drugs, especially ibandronate
(and recently also zoledronate) have attained a proper
position in the treatment of osteoporosis, the latter also
in the treatment of osteoporosis in men. Intravenous
forms are particularly useful in cases of intolerance to
oral bisphosphonates or in concomitant absorption dis-
orders. In steroid-using patients, a more effective BMD
improvement has been demonstrated, both in the spine
and in the femoral neck, in the course of a three-year i.v.
ibandronate therapy, combined with a calcium supple-
ment vs. the effect of alphacalcidol plus calcium [56].
Moreover, a certain reduction has been demonstrat-
ed in the number of patients with spinal fractures in
the group treated with i.v. ibandronate vs. alphacalci-
dol (8.6% vs. 22.8%; p < 0.05). Recently, beside the
above-mentioned drugs, zoledronate and teriparatide
have been approved for the treatment of post-steroid
osteoporosis (Table II).
It has been demonstrated that zoledronate, admin-
istered once a year at an intravenous 5 mg dose, increas-
es BMD in the spine and in the proximal femur much
more effectively than risedronate, both in prevention
(steroids < 3 months) and in treatment (steroids ≥ 3 mon-
ths). In the course of an annual observation, only eight
new spinal fractures were noted in 771 patients and no
statistically significant differences were observed be-
tween the group submitted to prevention and the group
Table II. Approved therapies of post-steroid osteoporosis
Tabela II. Zaakceptowane formy leczenia osteoporozy
posteroidowej
Dose Route of
administration
Alendronate 5 or 10 mg daily Oral
70 mg once a week
Etidronate 400 mg daily for two Oral
weeks, every three months
Risedronate 5 mg daily Oral
35 mg once a week
Zoledronate 5 mg once a year Intravenous
(in women and men) infusion
Teriparatide 20 µg daily Subcutaneous
Table I. Recommendations for treatment of post-steroid osteoporosis (comparison of data in the USA, UK and Denmark) (acc.
to [41, 43, 48])
Tabela I. Rekomendacje leczenia osteoporozy posteroidowej (porównanie zaleceń Stanów Zjednoczonych, Wielkiej Brytanii
i Danii) [41, 43, 48]
American Society of Rheumatology Royal College of Physicians (UK)
Steroid dose ≥ 5 mg/day for ≥ 3 months Each dose for ≥ 3 months
Primary prevention criteria All patients Age ≥ 65 years or with fractures in history
Indications to secondary prevention BMD T-score < –1 BMD T-score £ –1.5 (£ –2.5 following Danish
recommendations for patients receiving
< 7.5 mg of prednisolone)
Ca and vitamin D supplementation All patients Patients with insufficient supplementation
of calcium in diet and/or with
vitamin D deficiency
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submitted to therapy. Taking into account the frequent-
ly observed concomitance of other diseases in steroid-
treated patients, which means there are increased quan-
tities of administered drugs, the incidence of adverse
effects may be higher than average. Therefore, it is as-
sumed that steroid therapy could increase the risk of
mandibular necrosis or atypical fractures [57, 58]. More-
over, because it is possible that bisphosphonates can
permeate through the placenta in premenopausal wom-
en, their use should be approached with particular cau-
tion.
Calcium and vitamin D
and its active metabolites
Calcium and vitamin D applications play a significant
role in the course of steroid therapy. Cochrane’s data-
base analysis indicates a statistically significant partici-
pation of calcium and vitamin D in BMD improvement,
both in the spine and in the femoral neck [59]. Even
beyond this, calcium and native vitamin D have rou-
tinely been used in many studies looking at the pre-
vention and treatment of post-steroid osteoporosis [47].
Active forms of vitamin D play a significant role in
steroid-induced osteoporosis. It has been found that
calcitriol, administered in doses of 0.5–1 mg daily, im-
proves BMD, particularly in the lumbar spine [60–62],
although the obtained results were not always satisfac-
tory [63]. No such effects of the active forms of vitamin D
have been found regarding the fracture risk in steroid-
treated patients. Similarly, alphacalcidol, in doses from
0.25 to 1 mg daily, protects against bone mass loss in the
spine and, according to some reports, also in the fore-
arm and the femoral neck [64–66]. Although a decreased
risk of spinal and extravertebral fractures was observed
after two years of using alphacalcidol with calcium, , the
results obtained from a three-year observation were not
statistically significant [67]. Comparing the effect of al-
endronate with that of alphacalcidol, a more efficient
improvement of BMD was observed in the lumbar spine,
following bisphosphonate therapy [68, 69]. The evidence
which would indicate any supremacy of the active forms
of vitamin D over that of the native form of vitamin D is
rather weak. Therefore, neither alphacalcidol not calcitriol
has been approved for the therapy of post-steroid os-
teoporosis in Europe or North America.
When using active forms of vitamin D, calcium con-
centration in serum and in daily urine volume should
be monitored for the possibility of hypercalcaemia or
hypercalciuria. It should also be kept in mind that ste-
roids can themselves enhance calcium escape with
urine. It should be emphasised as well that the favour-
able pleiotropic effects of native vitamin D are highlight-
ed in the Polish therapeutic recommendations [70–71].
Other forms of therapy
Other forms of therapy recommended during chronic
steroid administration include calcitonin, oestrogens
and fluorine [72]. An analysis of Cochrane’s base found
that the favourable effect of calcitonin in post-steroid
osteoporosis consists in counteracting bone mass loss
in the spine and the forearm, with no effect on the fem-
oral neck. No benefits have been confirmed in terms of
spinal or extravertebral fracture risk [73]. Despite infor-
mation as to the strong, favourable, anabolic effects of
the parathormone and its formal approval to the thera-
py of post-steroid osteoporosis, PTH agents are not com-
monly used [74]. In steroid-treated women, an increased
BMD has been observed in the lumbar spine after one
year of PTH administration and in the femoral neck af-
ter two years [75–76]. Studies have reported that post-
menopausal women, receiving oral prednisolone and
HRT, who were administered teriparatide at a dose of
40 mg/d i.e. the human, recombined PTH with mole-
cule of 1–34 amino acids, obtained an increase in spine
BMD after one year of therapy. That effect was main-
tained for another year after drug withdrawal. In turn,
in the femoral neck, despite PTH withdrawal after one
year of therapy, a statistically significant increase was
also found after three years of the still continued study.
Comparing the effects of teriparatide at a dose of
20 mg/day against those of alendronate, a higher and
statistically significant increase in spine BMD was al-
ready being observed after six months, while a similar
effect in the femoral neck was obtained only after one
year of therapy [77]. BMD changes were comparable in
women, both before and after the menopause, as well
as in men [78]. It should be emphasised that, after PTH,
the incidence of fractures was lower than after alendr-
onate (0.6% vs. 6.1%, respectively; p < 0.005). It has been
noted that the positive effect of the parathormone on
BMD in women is better expressed in post-steroid than
in post-menopausal osteoporosis, what may be associ-
ated with the way PTH suppresses steroid effects on
osteoblastogenesis and on the apoptosis of osteoblasts
and osteocytes [9].
Another study again demonstrated that advantage,
comparing the effect of a 36-month therapy with teri-
paratide to the effect of 36-month alendronate admin-
istration on BMD improvement in the spine and in the
femoral neck, as well as on the reduction of vertebral
fracture risk [79]. This found that, in both therapies, early
changes of certain bone metabolism markers correlat-
ed with BMD increased after 18 months [80]. As expect-
ed, bone metabolism markers changed according to the
activity of the received drug (PTH being an anabolic
agent, whereas alendronate is an antiresorptive agent)
[80-81].
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Despite certain differences in the approach to pa-
tients in the course of chronic steroid therapy, signifi-
cant roles have been assigned to: 1) primary prophy-
lactics; 2) bisphosponates as first-line therapy; and 3)
supplementation with calcium and vitamin D [82–83].
The roles of bone metabolism markers and of densi-
tometric examinations in the monitoring are not abso-
lutely clear, although spine densitometry at the stage
of therapy implementation may have significance for
the decision regarding prevention options. It seems that
not only is the appropriate implementation of prophy-
lactics important, but so also is regularity of its applica-
tion. It has been found that the prophylactics of bone
mass loss is suboptimal when oral steroids are used [84].
A positive correlation has been demonstrated be-
tween bisphosphonate therapy withdrawal in patients
on chronic steroid therapy and young age, a large num-
ber of concomitant diseases, and the unavailability of
densitometric examination.
Understanding the disease is a very important ele-
ment in the prophylactics of osteoporosis, especially
post-steroid osteoporosis. A programme based on iden-
tifying patients with risk factors, a proper education,
a planned care system and control of recommendations
after one year of their application, has been shown to
considerably improve the knowledge of patients about
osteoporosis. Additionally, increased vitamin D concen-
trations and better physical activity have been observed
in these patients. In 91% of patients in the high risk
group, an implementation of prophylactic treatment
brought about an improvement in bone mineral densi-
ty of the lumbar spine and the femoral neck [85].
Regarding the prophylactics of post-steroid os-
teoporosis, in addition to a proper diet or calcium and
vitamin D substitution, a considerable role can be at-
tributed to physical activity, prevention of falls and
minimising the steroid dose, while keeping it therapeu-
tically effective. If possible, the oral mode should be re-
placed by another form of administration, e.g. inhala-
tion.
In the treatment of osteoporosis, cost-effectiveness
should be regarded as a very important factor. It has
been demonstrated that the relatively high cost of bis-
phosphonates is cost-effective in the group of patients
with high fracture risk [86]. This group includes  elder-
ly patients (those expected to survive at least five years),
younger patients with fractures in their history, those
with small body weight, rheumatoid arthritis or who
are using high doses of steroid.
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